NxThera Inc., a Shoreview, Minnesota-based startup developing a thermal vapor prostate treatment, is bringing in millions of extra investment dollars, including from a corporate partner.

NxThera Inc. has raised $2 million from the sale of equity and warrants, according to documents filed with the Securities and Exchange Commission. The startup based in St. Paul is developing ways to treat enlarged prostates by using vapor injections and thermal energy to kill tissue.

NxThera Inc. has raised $1 million from the sale of equity and debt, according to documents filed with the Securities and Exchange Commission.The start-up, based in St. Paul, is developing ways to treat enlarged prostates by using vapor injections and thermal energy to kill tissue.CEO Robert Paulson formerly led Restore Medical Inc., a company based [...]

Delphinus Medical Technologies Inc. has received $8 million in funding commitments to further develop an ultrasonic breast cancer detection device that could become an alternative to mammograms.The funding means that Delphinus can finally begin the process of commercializing its SoftVue device, which has undergone about 10 years of research and development.Unlike mammography, which is traditionally [...]

Obstetricians, nurse-midwives and labor and delivery nurses now have a powerful — and inexpensive — tool for assessing a woman’s risk of delivering a baby too early. CerviLenz.The disposable device made by CerviLenz Inc. — a Chagrin Falls, Ohio, startup — was introduced today at the American Academy of Obstetricians and Gynecologists annual meeting in [...]

Dr. Brian Duncan caught the business bug as the only clinician on a team of Cleveland Clinic researchers who set out in 2004 to develop a heart-assist pump for infants with heart failure.The Clinic wooed Duncan, a pediatric heart surgeon, and his cardiac anesthesiologist wife to Cleveland in 2001. A few years later, the National [...]

Esperion Therapeutics Inc., a spin-off from Pfizer Inc., has raised an additional $5 million to develop drugs that treat cardiovascular and metabolic disease, according to a SEC filing. The regulatory document states that Esperion has raised $27.75 million in equity and debt, but that dollar figure likely includes a $22.75 million Series A fundraise the company announced in 2008 after the spin-off.

Aastrom, which is developing therapies that use stem cells to treat cardiovascular diseases, priced its shares at 26 cents per unit and hopes to raise $10.9 million from the offering.

Early stage health investor Arboretum Ventures has added George Dunbar, former chief executive of Michigan biotech company Aastrom Biosciences Inc., as a partner.

The company said it needed to raise the money to keep up with demand. Accuri launched its Accuri C6 Flow Cytometer in April 2008 and followed that launch three months later with a $13 million raise to expand its marketing and sales efforts of the product.